Investor Presentaiton

WK 40 WK 28 WK 16 WK 4 DAY 1 SCR WK-8 No. of patients Daprodustat ESA 1477 1475 1449 1381 1323 1270 1225 1175 1125 1059 998 838 601 419 230 WK 64 WK 76 WK 52 1487 1485 1453 1403 1336 1274 1241 1191 1138 1092 1039 863 612 432 248 Co-primary Efficacy Endpoint: ASCEND-D Mean Hb change from baseline to the evaluation period (Weeks 28-52) - ITT Population Hb concentration (g/dL) Daprodustat was noninferior to ESA for mean change in Hb from baseline to the evaluation period (Weeks 28-52) 12 asceND D ✰ Daprodustat ESA 11.5 11 10.5 10 9.5 9 DIALYSIS EP Prespecified NI margin: -0.75 g/dL Adjusted Mean Treatment Difference (95% CI)* 0.18 (0.12, 0.24) Noninferiority was achieved because the lower limit of the 95% CI of the treatment difference was greater than the prespecified noninferiority margin of -0.75 g/dL WK 148 WK 136 WK 112 WK 124 WK 100 WK 88 *Based on an ANCOVA model using observed and imputed data with terms for treatment, baseline hemoglobin, dialysis type and region. Error bars indicate 95% CI. Post-randomization values include on- and off- treatment values. Visits on or before Day 1 include only pre-treatment values. Horizontal reference lines represent the Hb analysis range (10-11.5g/dL). The Hb target range for dose changes is 10-11g/dL. Vertical dotted lines represent the EP. Cl, confidence interval; EP, evaluation period; EOS, end of study; ESA, erythropoiesis-stimulating agent; FU, follow up; Hb, hemoglobin; ITT, intent-to-treat; NI noninferiority; SCR screening; Wk, week. FU EOS 862 639 839 628 11

View entire presentation